Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives-Reference-Cited by-同舟云学术

Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives

Published:2018-10 Issue: Volume:158 Page:322-333
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Guo Ming,Zuo Daiying,Zhang Junlong,Xing Lingyun,Gou Wenfeng,Jiang Feng,Jiang Nan,Zhang Dajun,Zhai Xin

Funder

National Natural Science Foundation of China

Key Research Plan Project of Department of Science & Technology of Liaoning Province

Natural Science Foundation of Liaoning Province

Development Project of Ministry of Education Innovation Team

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference38 articles.

1. Tyrosine kinase gene rearrangements in epithelial malignancies;Shaw;Nat. Rev. Canc.,2013

2. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N. Engl. J. Med.,2010

3. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma;Morris;Science,1995

4. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

5. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cance;Rikova;Cell,2007

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation;European Journal of Medicinal Chemistry;2024-09

2. Recent advances in the development of dual ALK/ROS1 inhibitors for non-small cell lung cancer therapy;European Journal of Medicinal Chemistry;2023-09

3. Recent Updates on Structural Aspects of ALK Inhibitors as an Anticancer Agent;Anti-Cancer Agents in Medicinal Chemistry;2023-05

4. Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants;European Journal of Medicinal Chemistry;2022-08

5. Transition-metal-free regioselective hydroamination of styrenes with amino-heteroarenes;Chemical Communications;2022